VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program through a collaboration with ATUM. The partnership will utilize ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines that support IND/CTA-enabling activities and future clinical development. This milestone follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
The cell line development is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies. VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. This conditional "AND"-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
The company believes this innovative approach addresses a key challenge in cancer immunotherapy: balancing efficacy with safety. Traditional T-cell engagers can activate T cells in healthy tissues, leading to severe side effects. By requiring dual tumor antigen binding, VERAXA's BiTAC platform aims to restrict T-cell activation to tumor cells, sparing normal tissues. This selectivity could allow for higher doses and improved treatment outcomes.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. For more information, visit the company's newsroom at https://ibn.fm/VRXA.
The full press release is available at https://ibn.fm/FCIlk. This development marks an important step toward clinical testing of a novel cancer therapy that could offer a better safety profile and expanded therapeutic window for patients.
